Zobrazeno 1 - 10
of 42
pro vyhledávání: '"G R, Khachatryan"'
Autor:
V. A. Lemeshko, K. I. Matrenin, V. V. Omelyanovskiy, Yu. V. Vasilyeva, G. R. Khachatryan, L. A. Kolganov
Publikováno v:
Фармакоэкономика, Vol 14, Iss 1, Pp 5-15 (2021)
Objective: the development and approbation of the method for comparative analysis of the lists of medicines in different countries and systems of healthcare.Material and methods. Based on the open-access data on the lists of medicines published on of
Externí odkaz:
https://doaj.org/article/4d3a1b6cbab54f6e9923d643b6f8e9f2
Autor:
V. V. Omelyanovskiy, E. A. Maksimkina, O. I. Ivakhnenko, M. V. Avxentyeva, M. V. Sura, G. R. Khachatryan
Publikováno v:
Фармакоэкономика, Vol 13, Iss 2, Pp 113-123 (2020)
The article presents a description of amendments of the Russian Federation Government Decree No. 871 from August 28, 2014 (with amendments from November 20, 2018). The authors analyzed the historical development of approaches for complex drug assessm
Externí odkaz:
https://doaj.org/article/dfcced40080b496c975e509b8261a9cd
Publikováno v:
Фармакоэкономика, Vol 13, Iss 1, Pp 71-83 (2020)
The article presents the description of structural, organizational and methodological issues of health technology assessment (HTA) of French drugs as well as the state-reimbursable list of drugs. The HTA is conducted by an independent public body –
Externí odkaz:
https://doaj.org/article/225d73b4875e4c75aef5208a5d51faad
Publikováno v:
Фармакоэкономика, Vol 12, Iss 4, Pp 333-341 (2020)
In Australia, the federal government is in charge of providing the health care to patients. The government agencies determine the list of reimbursable pharmaceuticals and medical services and also define the preferential categories of the population.
Externí odkaz:
https://doaj.org/article/e7de7dc2b45540fd84ba5f53b919248c
Publikováno v:
Фармакоэкономика, Vol 12, Iss 2, Pp 146-154 (2019)
Aim: analyze the structure and funding of health technology assessment (HTA) agencies abroad.Materials and methods. Here, we review the organizational structure and funding of HTA agencies in Europe (Austria, Belgium, Germany, Ireland, the Netherland
Externí odkaz:
https://doaj.org/article/199a7e31ef2744ca9e60d956e3e24d2b
Publikováno v:
Фармакоэкономика, Vol 12, Iss 2, Pp 156-164 (2019)
The Italian healthcare system is historically structured by the difference in economic development between the northern and southern parts of this country. The Italian Medicines Agency (AIFA) is the national health technology assessment (HTA) authori
Externí odkaz:
https://doaj.org/article/94b9f5e1aafc40d7b75e8f6f6b5bba69
Publikováno v:
Фармакоэкономика, Vol 12, Iss 1, Pp 14-26 (2019)
The integrated Model of health care for patients with inflammatory bowel disease (IBD) is based on the creation of specialized centers where multidisciplinary teams provide patient-centered care. Recent studies showed that the introduction of such ap
Externí odkaz:
https://doaj.org/article/911aafef1aac4d02b8245a13e7ab5af7
Autor:
N. Z. Musina, V. K. Fedyaeva, V. V. Omel’yanovskii, G. R. Khachatryan, K. V. Gerasimova, V. A. Lemeshko, K. P. Konchits
Publikováno v:
Фармакоэкономика, Vol 10, Iss 3, Pp 66-74 (2017)
A set of criteria for assessing the innovative potential of drugs (therapeutic value) have been developed and are widely used elsewhere. These approaches allow the state (the payer) to assess the clinical significance of a new medical product and mak
Externí odkaz:
https://doaj.org/article/5229337fec764b4ea60ec04d13d28c0c
Publikováno v:
Фармакоэкономика, Vol 10, Iss 2, Pp 69-74 (2017)
Among the most important aspects of the health policy are the methods for pricing of medicines, especially of innovative medicines. In many countries, the “therapeutic value” of a medicine is commonly used as a major criterion in negotiations on
Externí odkaz:
https://doaj.org/article/bd6f5cac7583437fa80b070a5fce3c2e
Autor:
V. S. Dombrovskiy, G. R. Khachatryan
Publikováno v:
Фармакоэкономика, Vol 9, Iss 4, Pp 46-53 (2017)
This publication presents a comparison of recommendations of screening programs and prevention activities in the United States, Canada, the Netherlands and Germany for adult non-pregnant population excluding infectious diseases. Sources of funding fo
Externí odkaz:
https://doaj.org/article/4e736550100b436fb5ab9a090c129acf